| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ... Journal of hepatology 73 (1), 202-209, 2020 | 3185 | 2020 |
| The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 SG Sepanlou, S Safiri, C Bisignano, KS Ikuta, S Merat, M Saberifiroozi, ... The Lancet gastroenterology & hepatology 5 (3), 245-266, 2020 | 1262 | 2020 |
| Treatment of NAFLD with diet, physical activity and exercise M Romero-Gómez, S Zelber-Sagi, M Trenell Journal of hepatology 67 (4), 829-846, 2017 | 1226 | 2017 |
| EASL Clinical Practice Guidelines on nutrition in chronic liver disease M Merli, A Berzigotti, S Zelber-Sagi, S Dasarathy, S Montagnese, ... Journal of hepatology 70 (1), 172-193, 2019 | 836 | 2019 |
| Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study S Zelber-Sagi, D Nitzan-Kaluski, R Goldsmith, M Webb, L Blendis, ... Journal of hepatology 47 (5), 711-717, 2007 | 665 | 2007 |
| Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence S Zelber-Sagi, V Ratziu, R Oren World journal of gastroenterology: WJG 17 (29), 3377, 2011 | 558* | 2011 |
| Advancing the global public health agenda for NAFLD: a consensus statement JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, ... Nature Reviews Gastroenterology & Hepatology 19 (1), 60-78, 2022 | 462 | 2022 |
| A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease S Zelber–Sagi, A Kessler, E Brazowsky, M Webb, Y Lurie, M Santo, ... Clinical Gastroenterology and Hepatology 4 (5), 639-644, 2006 | 433 | 2006 |
| Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures S Zelber‐Sagi, D Nitzan‐Kaluski, Z Halpern, R Oren Liver International 26 (7), 856-863, 2006 | 384 | 2006 |
| Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis M Webb, H Yeshua, S Zelber-Sagi, E Santo, E Brazowski, Z Halpern, ... American Journal of Roentgenology 192 (4), 909-914, 2009 | 376 | 2009 |
| The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality TH Karlsen, N Sheron, S Zelber-Sagi, P Carrieri, G Dusheiko, E Bugianesi, ... The Lancet 399 (10319), 61-116, 2022 | 358 | 2022 |
| Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up S Zelber-Sagi, R Lotan, A Shlomai, M Webb, G Harrari, A Buch, ... Journal of hepatology 56 (5), 1145-1151, 2012 | 331 | 2012 |
| Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study S Zelber-Sagi, D Nitzan-Kaluski, R Goldsmith, M Webb, I Zvibel, I Goldiner, ... Hepatology 48 (6), 1791-1798, 2008 | 330 | 2008 |
| The fatty acid–bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease R Safadi, FM Konikoff, M Mahamid, S Zelber-Sagi, M Halpern, T Gilat, ... Clinical Gastroenterology and Hepatology 12 (12), 2085-2091. e1, 2014 | 319 | 2014 |
| The Mediterranean dietary pattern as the diet of choice for non‐alcoholic fatty liver disease: evidence and plausible mechanisms S Zelber‐Sagi, F Salomone, L Mlynarsky Liver International 37 (7), 936-949, 2017 | 272 | 2017 |
| Natural antioxidants for non‐alcoholic fatty liver disease: molecular targets and clinical perspectives F Salomone, J Godos, S Zelber‐Sagi Liver International 36 (1), 5-20, 2016 | 269 | 2016 |
| High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance S Zelber-Sagi, D Ivancovsky-Wajcman, NF Isakov, M Webb, D Orenstein, ... Journal of hepatology 68 (6), 1239-1246, 2018 | 261 | 2018 |
| Non-alcoholic fatty liver disease: A patient guideline SM Francque, G Marchesini, A Kautz, M Walmsley, R Dorner, JV Lazarus, ... JHEP reports 3 (5), 100322, 2021 | 195 | 2021 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 178 | 2022 |
| Re‐evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large‐scale population study R Kariv, M Leshno, A Beth‐Or, H Strul, L Blendis, E Kokia, D Noff, ... Liver international 26 (4), 445-450, 2006 | 178 | 2006 |
